Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1907
Name malignant fibrous histiocytoma
Definition
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer sarcoma malignant fibrous histiocytoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Binimetinib + Encorafenib malignant fibrous histiocytoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02406781 Phase II Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) Unknown status FRA 0
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Completed USA 0
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Active, not recruiting USA | ITA | CAN | AUS 0
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Completed ITA | GBR | ESP 0
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03474094 Phase II Atezolizumab Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) Recruiting GBR | FRA 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT05017103 Phase II Sintilimab Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study Terminated USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05182164 Phase II Cabozantinib + Pembrolizumab Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) Recruiting FRA 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05488366 Phase I Pembrolizumab Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma Recruiting USA 0
NCT05711615 Phase I Pegylated liposomal doxorubicin + Peposertib Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Recruiting USA 0
NCT05809830 Phase Ib/II Doxorubicin Doxorubicin + LB-100 Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) Recruiting ESP 0
NCT05821231 Phase I MEDI5752 Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) Recruiting FRA 0
NCT05836571 Phase II Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Recruiting USA | CAN 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0
NCT06113809 Phase I Palbociclib + Pembrolizumab Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS) Recruiting USA 0
NCT06116578 Phase II Pembrolizumab Olaparib + Pembrolizumab Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc) Not yet recruiting FRA 0
NCT06263231 Phase III Eribulin Trabectedin Pazopanib INT230-6 A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) Recruiting USA 0
NCT06273852 Phase I PBA-0405 A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Recruiting USA 0
NCT06422806 Phase III Doxorubicin Doxorubicin + Pembrolizumab Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Recruiting USA 0
NCT06660810 Phase I Talimogene laherparepvec Neoadjuvant Intralesional Injection of Talimogene Laherparepvec Not yet recruiting USA 0